S2-serotonergic receptor inhibition (ketanserin), combined with thromboxane A2/prostaglandin endoperoxide receptor blockade (BM 13.177): enhanced anti-platelet effect.
D004357:Drug Synergism; D006801:Humans; D007650:Ketanserin / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D011982:Receptors, Prostaglandin / Q000187:drug effects*; D011985:Receptors, Serotonin / Q000187:drug effects*; D013449:Sulfonamides / Q000494:pharmacology*
D011982:Receptors, Prostaglandin; D011985:Receptors, Serotonin; D013449:Sulfonamides; C040624:sulotroban; D007650:Ketanserin